Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
02
11
2022
revised:
21
11
2022
accepted:
04
12
2022
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
28
2
2023
Statut:
epublish
Résumé
The conditioning regimens with different alkylators at different doses can influence the outcome of allogeneic stem cell transplantation (SCT), but conclusive data are missing. With the aim to analyze real-life allogeneic SCTs performed in Italy between 2006 and 2017 in elderly patients (aged >60 y) with acute myeloid leukemia or myelodysplastic syndrome, we collected 780 first transplants data. For analysis purposes, patients were grouped according to the type of alkylator included in the conditioning (busulfan [BU]-based; n = 618; 79%; treosulfan [TREO]-based; n=162; 21%). No significant differences were observed in nonrelapse mortality, cumulative incidence of relapse, and overall survival, although in the TREO-based group, we observed a greater proportion of elderly patients ( Despite a higher number of risk factors in the TREO group, no significant differences were observed in nonrelapse mortality, cumulative incidence of relapse, and overall survival according to the type of alkylator, suggesting that TREO has no advantage over BU in terms of efficacy and toxicity in acute myeloid leukemia and myelodysplastic syndrome.
Identifiants
pubmed: 36845852
doi: 10.1097/TXD.0000000000001451
pmc: PMC9949804
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1451Informations de copyright
Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Cancer Chemother Pharmacol. 2008 Oct;62(5):821-30
pubmed: 18246351
Clin Pharmacokinet. 2018 Oct;57(10):1255-1265
pubmed: 29557088
Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):333-47
pubmed: 23157726
Bone Marrow Transplant. 2020 Jun;55(6):1093-1102
pubmed: 31969678
Haematologica. 2021 Jul 01;106(7):1794-1804
pubmed: 33730842
N Engl J Med. 2016 Jan 7;374(1):43-53
pubmed: 26735993
Biol Blood Marrow Transplant. 2020 Sep;26(9):e215-e221
pubmed: 32561339
Front Oncol. 2020 Dec 16;10:591363
pubmed: 33425740
Methods Mol Biol. 2018;1802:1-10
pubmed: 29858798
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Front Immunol. 2020 Apr 09;11:636
pubmed: 32373119
Biol Blood Marrow Transplant. 2019 Mar;25(3):e71-e72
pubmed: 30562588
Transplant Cell Ther. 2022 Feb;28(2):96.e1-96.e11
pubmed: 34818581
Front Oncol. 2022 Jun 17;12:874117
pubmed: 35785189
Am J Hematol. 2021 Jan;96(1):69-79
pubmed: 33064301
Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):139-41
pubmed: 19147094
Blood. 2014 Jul 17;124(3):344-53
pubmed: 24914142
Biol Blood Marrow Transplant. 2018 Apr;24(4):751-757
pubmed: 29247780
Lancet Haematol. 2020 Feb;7(2):e157-e167
pubmed: 32004485
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):321-326
pubmed: 28641099
Bone Marrow Transplant. 2016 Jun;51(6):786-92
pubmed: 26901709
Lancet Haematol. 2020 Jan;7(1):e28-e39
pubmed: 31606445
Bone Marrow Transplant. 2020 Jun;55(6):1114-1125
pubmed: 31996792